# AMA1-C1/Alhydrogel + CpG 7909 for Malaria

> **NCT00344539** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 75 (actual)

## Conditions studied

- Plasmodium Falciparum Malaria

## Interventions

- **BIOLOGICAL:** AMA1-C1/Alhydrogel®
- **BIOLOGICAL:** CPG 7909 Oligodeoxynucleotide (VaxImmune®)

## Key facts

- **NCT ID:** NCT00344539
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2013-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00344539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00344539, "AMA1-C1/Alhydrogel + CpG 7909 for Malaria". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00344539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*